Phase II Study of Reduced MBF Regimen for Patients Over 50 Years With Myeloid Malignancies
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
In this multiple-center phase II study, we plan to evaluate the clinical outcome of reduced
intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan
(100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML over 50 years.